摘要
目的:探讨参芪降糖胶囊联合地特胰岛素治疗初发2型糖尿病伴肥胖症的效果。方法:选取2020年6月—2022年6月在中国人民解放军第九六〇医院接受治疗的100例初发2型糖尿病伴肥胖症患者为研究对象,根据随机分层法分为对照组(n=50)与研究组(n=50)。对照组采用地特胰岛素治疗,研究组在对照组的基础上联合参芪降糖胶囊治疗。比较两组用药前后的血糖水平、胰岛功能指标水平、血脂水平及体重指数(BMI)、血糖达标时间。结果:用药后两组空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)水平明显比用药前低,研究组低于对照组,差异有统计学意义(P<0.05)。用药后两组胰岛素抵抗指数(HOMA-IR)水平均比用药前低,且研究组较对照组更低,两组胰岛素β细胞功能(HOMA-β)、空腹胰岛素(FINS)水平比用药前高,且研究组较对照组更高,差异有统计学意义(P<0.05)。两组用药后甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)水平均较用药前降低,研究组比对照组低,两组高密度脂蛋白胆固醇(HDL-C)水平较用药前上升,研究组比对照组高,差异有统计学意义(P<0.05)。两组用药后BMI均下降,且研究组低于对照组,差异有统计学意义(P<0.05)。研究组血糖达标时间比对照组短,差异有统计学意义(P<0.05)。结论:针对初发2型糖尿病伴肥胖症患者采用参芪降糖胶囊联合地特胰岛素进行治疗,不仅能够有效稳定患者血糖与血脂水平,还能降低体重,改善胰岛功能。
Objective:To investigate the clinical effect of Shenqi Jiangtang Capsules combined with Insulin Detemir in the treatment of incipient type 2 diabetes with obesity.Method:A total of 100 patients with incipient type 2 diabetes with obesity treated in the 960th Hospital of the People's Liberation Army of China from June 2020 to June 2022 were selected as the study objects,and they were divided into control group(n=50)and study group(n=50)according to random stratification method.The control group was treated with Insulin Detemir,and the study group was treated with Shenqi Jiangtang Capsules on the basis of the control group.Blood glucose level,islet function index level,blood lipid level,body mass index(BMI)before and after medication,blood glucose standard time were compared between the two groups.Result:The levels of fasting plasma glucose(FPG),2 h postprandial blood glucose(2 h PG)and glycosylated hemoglobin(HbA1c)in the two groups after medication were significantly lower than those before medication,and the levels in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).After medication,insulin resistance index(HOMA-IR)in both groups were lower than those before medication,and that in the study group was lower than that in the control group,insulin beta cell function(HOMA-β)and fasting insulin(FINS)levels in both groups were higher than those before medication,and those in the study group were higher than those in the control group,the differences were statistically significant(P<0.05).After medication,the levels of triglyceride(TG),low-density lipoprotein cholesterol(LDL-C)and total cholesterol(TC)in both groups were lower than those before medication,those in the study group were lower than those in the control group,and the levels of high density lipoprotein cholesterol(HDL-C)in both groups were higher than before medication,that in the study group was higher than that in the control group,and the differences were statistically significant(P<0.05).BMI of both groups decreased after medication,and that in the study group was lower than that in the control group,the differences were statistically significant(P<0.05).The blood glucose standard time of the study group was shorter than that of the control group,and the difference was statistically significant(P<0.05).Conclusion:Shenqi Jiangtang Capsules combined with Insulin Detemir not only can effectively stabilize the blood glucose and lipid levels of patients with incipient type 2 diabetes and obesity,but also reduce body weight and improve islet function.
作者
徐芹
周璐
XU Qin;ZHOU Lu(The 960th Hospital of the People's Liberation Army of China,Jinan 250031,China;不详)
出处
《中外医学研究》
2024年第3期122-125,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
初发2型糖尿病
肥胖症
参芪降糖胶囊
地特胰岛素
血糖
Incipient type 2 diabetes
Obesity
Shenqi Jiangtang
Capsulses
Insulin Detemir
Blood glucose
